RxDoctor Payments Data

Jerrica Ewald

Family · Langhorne, PANPI 1356087068

Payments from drug & device makers

$2,023in general payments, 2019–2025

Across 78 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$716
  • Sumitomo Pharma America, Inc.$271
  • AbbVie$240
  • Johnson & Johnson$195
  • Boston Scientific$103
  • Merck$68
  • plus $432 from 15 others

What the payments were for

  • Food & beverage$2,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,259
Medicare patients
275
Services billed
1,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron44$37,003
GemtesaVibegron42$26,121
Tamsulosin Hcl287$5,323
Finasteride142$2,839
Silodosin28$2,779
Trospium Chloride28$2,366
Methenamine Hippurate27$1,651
Testosterone12$1,562
Alfuzosin Hcl ErAlfuzosin Hcl54$1,033
Tadalafil37$790
Cefdinir52$758
Estradiol13$667
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$399
Doxycycline Hyclate26$153
CefuroximeCefuroxime Axetil12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$24$37,00344 claims
Sumitomo Pharma America, Inc.Gemtesa$271$26,12142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →